Skip to main content
TipRanks
Go Ultimate75% OFF

Medicinova (MNOV) AI Stock Analysis

335 Followers
MNOV

Medicinova

(NASDAQ:MNOV)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Negative Factors

Medicinova (MNOV) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%150%MNOV-3.12%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$68.66M
Dividend Yield
―
Average Volume (3M)
331.78K
Price to Earnings (P/E)
-6.4
Beta (1Y)
0.57
Revenue Growth
262.80%
EPS Growth
12.54%
Country
US
Employees
6
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Medicinova Business Overview & Revenue Model

Company Description

MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features...

Medicinova Risk Analysis

Medicinova disclosed 49 risk factors in its most recent earnings report. Medicinova reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Our business could be adversely affected by the effects of health pandemics or epidemics in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations, which could materially affect our operations globally, including at our headquarters in San Diego and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.Q4, 2024
2.We are a "smaller reporting company" and may take advantage of certain scaled disclosures available to us. We cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors.Q4, 2023
3.If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our results of operation could fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock.Q4, 2023

Medicinova Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

MNOV against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DTILDTIL58Neutral$211.33M-6.15-58.09%―6353.01%84.80%
ACRVACRV52Neutral$62.14M-0.77-70.14%――16.04%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CAMPCAMP46Neutral$238.47M-1.85-261.83%―39.93%16.95%
ALGSALGS38Underperform$14.80M-0.33-206.30%―1171.58%49.20%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%MNOVDTILALGSACRVCAMPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
MNOV and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
MNOVMedicinova1.40-0.01-1.06%
DTILPrecision Biosciences7.572.4347.18%
ALGSAligos Therapeutics, Inc.2.10-4.92-70.09%
ACRVAcrivon Therapeutics, Inc.1.45-0.93-39.08%
CAMPCAMP4 Therapeutics Corporation3.80-0.19-4.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.